17 results
PRE 14A
KDNY
Chinook Therapeutics Inc
17 Apr 23
Preliminary proxy
4:51pm
the fiscal year ended December 31, 2022 raised any conflict of interest.
The Compensation Committee may form and delegate authority to subcommittees … such transaction due to a conflict of interest. The policy provides that any request for us to enter into a transaction with an executive officer, director
S-3ASR
EX-4.4
KDNY
Chinook Therapeutics Inc
24 May 22
Automatic shelf registration
4:01pm
expose the Trustee to personal liability, or cause it to have a conflict of interest with respect to Holders of any then outstanding Series
8-K
EX-10.7
ggv30 wk21w
7 Oct 20
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
4:39pm
8-K
EX-10.6
ccvbp
7 Oct 20
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
4:39pm
8-K
EX-10.5
zdohh mp6mxftxelo1w
7 Oct 20
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
4:39pm
8-K
EX-10.7
qngr7gc
2 Jun 20
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
9:19am
8-K
EX-10.1
6dt4lels
2 Jun 20
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
9:19am
425
EX-10.7
ecxdbfyv ul2d855x1e
2 Jun 20
Business combination disclosure
9:17am
425
EX-10.1
btpi7zn2uix
2 Jun 20
Business combination disclosure
9:17am
DRS
EX-10
ekp01 ddkn
19 Dec 14
Draft registration statement
12:00am
- Prev
- 1
- Next